Two expert physicians with opposing viewpoints debate the risks and benefits of using cannabinoids for treating neuropathic and chronic pain.
At Psych Congress 2018, Andrew Penn from the UCSF School of Nursing provides insight into the use of CBD in clinical practice.
There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.
There are a number of challenges associated with the use of cannabidiol and hemp oils in pain management.
Cannabis and/or cannabinoids, when consumed through certain routes of administration, may reduce pain levels significantly.
There is rapidly growing interest in the use of marijuana and cannabinoids for pain.
Marijuana use is risky for young people and pregnant women.
For patients with chronic pain (CP), both mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT) improve physical functioning, pain intensity, and depression.
Although cannabinoids were found to improve the pain experience in individuals subjected to experimental pain, they were not found to have analgesic effects on existing experimental pain, suggesting that these agents may modulate affective processes.
Dispositional mindfulness may help reduce the risk for opioid misuse in patients with chronic pain by attenuating opioid craving and directing attention to naturally rewarding stimuli.